Higher levels of Bifidobacteria and tumor necrosis factor in children with drug-resistant epilepsy are associated with anti-seizure response to the ketogenic diet

From BugSigDB
Needs review
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Dahlin M, Singleton SS, David JA, Basuchoudhary A, Wickström R, Mazumder R, Prast-Nielsen S
Journal
EBioMedicine
Year
2022
Keywords:
Bifidobacterium, Bioinformatics, Epilepsy, Gut microbiota, Inflammation, Ketogenic diet, Machine learning, Omics, TNF
BACKGROUND: Recently, studies have suggested a role for the gut microbiota in epilepsy. Gut microbial changes during ketogenic diet (KD) treatment of drug-resistant epilepsy have been described. Inflammation is associated with certain types of epilepsy and specific inflammation markers decrease during KD. The gut microbiota plays an important role in the regulation of the immune system and inflammation. METHODS: 28 children with drug-resistant epilepsy treated with the ketogenic diet were followed in this observational study. Fecal and serum samples were collected at baseline and three months after dietary intervention. FINDINGS: We identified both gut microbial and inflammatory changes during treatment. KD had a general anti-inflammatory effect. Novel bioinformatics and machine learning approaches identified signatures of specific Bifidobacteria and TNF (tumor necrosis factor) associated with responders before starting KD. During KD, taxonomic and inflammatory profiles between responders and non-responders were more similar than at baseline. INTERPRETATION: Our results suggest that children with drug-resistant epilepsy are more likely to benefit from KD treatment when specific Bifidobacteria and TNF are elevated. We here present a novel signature of interaction of the gut microbiota and the immune system associated with anti-epileptic response to KD treatment. This signature could be used as a prognostic biomarker to identify potential responders to KD before starting treatment. Our findings may also contribute to the development of new anti-seizure therapies by targeting specific components of the gut microbiota. FUNDING: This study was supported by the Swedish Brain Foundation, Margarethahemmet Society, Stiftelsen Sunnerdahls Handikappfond, Linnea & Josef Carlssons Foundation, and The McCormick Genomic & Proteomic Center.

Experiment 1


Needs review

Curated date: 2024/12/09

Curator: Kavyaayala

Revision editor(s): WikiWorks, Kavyaayala

Subjects

Location of subjects
Sweden
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Response to ketogenic diet Response to ketogenic diet,response to ketogenic diet
Group 0 name Corresponds to the control (unexposed) group for case-control studies
pre-ketogenic diet responders (R_Ep1)
Group 1 name Corresponds to the case (exposed) group for case-control studies
post-ketogenic diet responders (R_Ep2)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Responders are children classified as having seizure reduction frequency greater than or equal to 50% after ketogenic diet treatment. This particular group refers to the samples taken from responders over eight years of age and post-treatment.
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
3 months

Lab analysis

Sequencing type
PCR
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
Not specified
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Welch's T-Test
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05


Signature 1

Needs review

Curated date: 2024/12/17

Curator: Kavyaayala

Revision editor(s): Kavyaayala, WikiWorks

Source: Figure 4C

Description: Fecal microbiome of R_Ep2 group compared to R_Ep1 group

Abundance in Group 1: decreased abundance in post-ketogenic diet responders (R_Ep2)

NCBI Quality ControlLinks
Bifidobacterium breve JCM 7019
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis ATCC 15697 = JCM 1222 = DSM 20088
Bifidobacterium longum subsp. longum JDM301

Revision editor(s): Kavyaayala, WikiWorks

Experiment 4


Needs review

Curated date: 2025/01/15

Curator: Kavyaayala

Revision editor(s): WikiWorks, Kavyaayala

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Epilepsy [X]Other epilepsy,[X]Other epilepsy (disorder),EF - Epileptic fit,EP - Epilepsy,Epilectic attack, NOS,EPILEP NEC W/O INTR EPIL,EPILEP NOS W/O INTR EPIL,epilepsy,Epilepsy (disorder),Epilepsy and recurrent seizures,EPILEPSY NEC W INTR EPIL,Epilepsy NOS,Epilepsy NOS (disorder),EPILEPSY NOS W INTR EPIL,Epilepsy, NOS,Epilepsy, unspecified,Epilepsy, unspecified, with intractable epilepsy,Epilepsy, unspecified, without mention of intractable epilepsy,Epileptic,Epileptic attack,Epileptic attack, NOS,Epileptic convulsions,Epileptic convulsions, NOS,Epileptic disorder,Epileptic disorder, NOS,Epileptic fit,Epileptic fits,Epileptic fits, NOS,Epileptic Seizure,Epileptic seizure (finding),Epileptic seizures,Epileptic seizures, NOS,Generalised convulsion,Generalised fit,Generalised seizure,Generalized convulsion,Generalized fit,Generalized seizure,Generalized seizure (finding),Other forms of epilepsy,Other forms of epilepsy (disorder),Other forms of epilepsy and recurrent seizures,Other forms of epilepsy NOS,Other forms of epilepsy NOS (disorder),Other forms of epilepsy, with intractable epilepsy,Other forms of epilepsy, without mention of intractable epilepsy,Seizure disorder,seizure disorder,Seizure disorder (disorder),Epilepsy
Group 0 name Corresponds to the control (unexposed) group for case-control studies
pre-ketogenic diet nonresponders (NR_Ep1)
Group 1 name Corresponds to the case (exposed) group for case-control studies
pre-ketogenic diet responders (R_Ep1)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Responders are children classified as having seizure reduction frequency greater than or equal to 50% after ketogenic diet treatment. This particular group refers to the samples taken from responders over eight years of age and pre-treatment.

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2025/01/15

Curator: Kavyaayala

Revision editor(s): Kavyaayala, WikiWorks

Source: Figure 4C

Description: Fecal microbiome of R_Ep1 group compared to NR_Ep1 group

Abundance in Group 1: increased abundance in pre-ketogenic diet responders (R_Ep1)

NCBI Quality ControlLinks
Bifidobacterium breve JCM 7019
Bifidobacterium longum DJO10A
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis ATCC 15697 = JCM 1222 = DSM 20088

Revision editor(s): Kavyaayala, WikiWorks